Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

27.27 +0.21 (+0.79%)
Streaming Delayed Price Updated: 11:38 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
This Dividend Giant Pfizer Could Turn a Boring Healthcare Allocation Into Serious Income ↗
Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive. 
Via The Motley Fool
Topics Intellectual Property
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
EQNX::TICKER_START (NASDAQ:HELP),(CBOE:HELP),(NYSE:TAK),(NASDAQ:CMPS),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee
In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus’ novel serotonergic agonist (“NSA”) portfolio This news release... 
Via FinancialNewsMedia
News headline image
Nasdaq, S&P 500 Futures Steady After AI Fears Roil Tech: Why IBM, NVDA, NFLX, HIMS, PFE Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ remained ‘bearish’ on Stocktwits. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
Novo Nordisk Shares Tumble 15.1% After CagriSema Fails to Topple Eli Lilly in Head-to-Head Trial
The undisputed reign of Novo Nordisk in the weight-loss drug sector faced its most severe challenge to date on February 23, 2026, as the company’s US-traded shares (NYSE: NVO) plummeted 15.1% in a... 
Via MarketMinute
News headline image
Kenvue Defies Market Headwinds with Q4 Earnings Beat as Kimberly-Clark Merger Looms
In a pivotal moment for the consumer health landscape, Kenvue (NYSE: KVUE) has reported a robust set of fourth-quarter results for 2025, signaling a successful turnaround and strategic resilience just... 
Via MarketMinute
Topics Earnings Economy World Trade
News headline image
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
1 Unpopular Stock That Should Get More Attention and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
Via The Motley Fool
News headline image
My 5 Favorite Dividend Stocks to Buy Right Now ↗
There are several solid prospects to choose from right now, but there's a reason I can't get these particular names out of my head. 
Via The Motley Fool
News headline image
Massive News: Pfizer's 6% Dividend Could Be Safer Than You Think ↗
Is Pfizer's 6% yield a rare opportunity hiding in plain sight, or are investors overlooking a major risk that could reshape its future? 
Via The Motley Fool
News headline image
Is Pfizer Stock an Underrated Healthcare Investment Play? ↗
Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success. 
Via The Motley Fool
Topics Intellectual Property
Explore the S&P500 index on Friday and find out which stocks are the most active in today's session. ↗
Via Chartmill
News headline image
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗
New products are already generating growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
News headline image
Top High-Yield Stocks to Double Up on Right Now ↗
If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead. 
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an... 
Via StockStory
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day. 
Via Stocktwits
News headline image
1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗
A robust pipeline is essential for a buy-and-hold pharmaceutical stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial ↗
Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial. 
Via Benzinga
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
From Pfizer Inc.
Via Business Wire
News headline image
2 S&P 500 Stocks to Research Further and 1 We Question
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
News headline image
2 Value Stocks Worth Your Attention and 1 We Brush Off
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful... 
Via StockStory
News headline image
The Great Inflation Thaw: US Price Pressures Hit Five-Year Low as Federal Reserve Eyes 2026 Pivot
The United States economy reached a long-awaited milestone this week as the Bureau of Labor Statistics reported that headline inflation fell to 2.4% in January 2026, with the core Consumer Price Index... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards
As the oncology community prepares to descend upon San Francisco for the 2026 ASCO Genitourinary (GU) Cancers Symposium from February 26–28, investors and clinicians alike are bracing for data that... 
Via MarketMinute
Topics Intellectual Property
News headline image
3 S&P 500 Stocks Worth Investigating
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.